Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
January 08, 2014 at 08:03 AM EST
Mast Therapeutics (NYSE MKT: MSTX ) today provided an update on the status of EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease. Consistent with prior guidance, the Company announced that 40 clinical sites were opened in the U.S. by year-end 2013. In addition, clinical
